Search Results

used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy

Classification of Tumours. Pathology and Genetics of Head and Neck Tumours . Lyon, France : IARC Press ; 2005 . 2. Wang YL Zhu YX Chen TZ . Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: experience of one cancer

the gastric cancer study in surgery and pathology. I. Clinical classification . Jpn J Surg 1981 ; 11 : 127 – 139 . 38 Soga J Kobayashi K Saito J . The role of lymphadenectomy in curative surgery for gastric cancer . World J Surg 1979

addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathology complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Aliance) . J Clin

hand-offs that occur during the intake and registration processes; obtaining patient materials (pathology tissue, radiology films) with complete interpretation in advance of the patient’s first visit; and wherever possible, performance of studies in

radiation oncology, medical oncology, pathology, radiology, and internal medicine subspecialties, potentially influencing overall survival in a manner that is independent of the institution’s case volume of the particular surgery of interest. Even if we

: 65 – 69 . 15. Morris E Maughan NJ Forman D Quirke P . Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? – The need for high quality pathology . Gut 2007 ; 56 : 1419 – 1425 . 16. Soreide K Janssen EA

picture of the molecular landscapes of cancer and many insights into the molecular pathology of cancers are accruing. Genomic databases such as cBioPortal ( www.cbiopartal.org ) 8 are providing access to large-scale genomic data where inferences can be

Pathology” (see BRAIN-F, pages 1334 and 1335) to provide background and recommendations for histologic characterization and molecular testing for gliomas. This article also describes data from clinical trials with available molecular information that have

kidney, hydronephrosis, metanephric tumors (ie, adenoma, stromal tumor, adenofibroma), multicystic kidney disease, polycystic kidney disease, renal hemorrhage, and renal vein thrombosis. Pathology To avoid potential tumor spread from malignant